Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2022-09-30 00:00:00 ET · period of report 2022-09-28 · accession 0001714899-22-000133 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-09-30 | 2022-09-28 | DNLI | Tessier-Lavigne Marc | Dir | S - Sale | $30.82 | -20.0K | 1.91M | -1% | -$616.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-28 | S | D | 4,423 | $31.08 | 1,910,356 | D | — | — | (F4) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.00 to $31.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 5,986 unvested restricted stock units. |
| 2 | Common | Common Stock | 2022-09-28 | S | D | 15,577 | $30.74 | 1,914,779 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 5,986 unvested restricted stock units. |